no more semaglutide A stronger 7.2 mg dose of Wegovy wins FDA approval after a 54-day review, promising greater weight loss for eligible patients. || FULL STORY IN COMMENTS 💊 Exciting news! Wegovy (semaglutide)

NCBI/LactMed: National Institute of Child Health and Human Development

This system adds cost but also adds safety

ALL NEW RELUMINS BEAUTY GLUTATHIONE DRINK- EASY TO USE, GREAT TASTING, SUPPORTS HEALTHY FIRM FRESH SKIN- POMEGRANATE FLAVOR This glutathione drink has a Natural Torula Yeast Glutathione, a strong antioxidant that helps inhibit hyper-pigmentation

In summary, we demonstrated that ghrelin and GLP-1 influence feeding regulation through their opposite effects on the cellular excitability of vagal afferent neurons

Sources Comparative review of semaglutide and tirzepatide mechanisms (Pharmacological Research, ScienceDirect) A Contemporary Rationale for Agonism of the GIP Receptor in the Treatment of Obesity (Diabetes, American Diabetes Association) GIP Receptor Agonism Attenuates GLP-1 Receptor Agonist-Induced Nausea and Emesis in Preclinical Models (PMC) Anorectic and aversive effects of GLP-1 receptor agonism mediated by brainstem CCK neurons, modulated by GIP (PMC) Head-to-Head Trial Compares Weight Loss Drugs (Weill Cornell Medicine Newsroom, reporting NEJM SURMOUNT-5) Head-to-head comparison of tirzepatide and semaglutide for weight loss: systematic review and meta-analysis (PubMed) Are You a GLP-1 Nonresponder

D., Hidalgo-Mora, J